Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

<strong>Background</strong> A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant. <br> &...

Full description

Bibliographic Details
Main Authors:	Emary, KRW, Golubchik, T, Aley, PK, Angus, B, Bibi, S, Bonsall, D, Cicconi, P, Clutterbuck, EA, Dold, C, Douglas, AD, Ewer, KJ, Flaxman, AL, Feng, S, Folegatti, PM, Fuskova, M, Green, CM, Green, CA, Greenland, M, Jenkin, D, Kerridge, S, Marchevsky, NG, Minassian, AM, Mujadidi, YF, Phillips, DJ, Plested, E, Robinson, H, Song, R, Snape, MD, Hill, AVS, Lambe, T, Gilbert, SC, Voysey, M, Ramasamy, MN, Pollard, AJ, Et al.
Other Authors:	COVID-19 Genomics UK consortium
Format:	Journal article
Language:	English
Published:	Elsevier 2021

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Similar Items